TULIP 2: Efficacy and Safety of Anifrolumab in Patients - a podcast by BMJ Group

TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.

In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.

Further episodes of ARD podcast

Further podcasts by BMJ Group

Website of BMJ Group